{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02661542: Phase 1/Phase 2 Interventional Completed Solid Tumors
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04335591: Phase 3 Interventional Completed Endometriosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
Status:
Investigational
Source:
INN:clonitazene [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Clonitazene is a synthetic opioid analgesic, structurally related to etonitazene. In the USA clonitazene is a schedule I narcotic controlled substance.
Class (Stereo):
CHEMICAL (RACEMIC)
Iomorinic Acid is triiodobenzamide derivative patented by Lentia G.m.b.H. as a radiographic contrast medium for liver imaging.
Class (Stereo):
CHEMICAL (RACEMIC)
Rocastine (AHR-11325) is a potent, nonsedating antihistamine with a rapid onset of action. This H1-antagonist effectively protected guinea pigs challenged with a lethal dose of histamine. It has also been mentioned in patents as a candidate to treat eye conditions and cough/cold mixtures (in which the lack of sedative effects from a non-sedating antihistamine would be especially useful in children, because daytime sedation is especially undesirable in this group). However, information on current use is not available and other second-generation, non-sedative antihistamines are available.
Status:
Investigational
Source:
NCT01225536: Phase 1 Interventional Completed Solid Tumor
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Int J Hematol. Nov 2022;116(5):754-769.: Phase 1 Human clinical trial Completed Graft vs Host Disease/therapy
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Int J Hematol. Nov 2022;116(5):754-769.: Phase 1 Human clinical trial Completed Graft vs Host Disease/therapy
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Int J Hematol. Nov 2022;116(5):754-769.: Phase 1 Human clinical trial Completed Graft vs Host Disease/therapy
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
